Journal of Medicines Optimisation - Mar 2022

Journal of Medicines Optimisation • Volume 8 • Issue 1 • March 2022 28 13. Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015;41:613–623. 14. NHS England. What is a Biosimilar Medicine? NHS England and NHS Improvement. 2019. Available at: https://www.england.nhs.uk/publication/what-is-a- biosimilar-medicine/ 15. NHS England (2017). Commissioning framework for biological medicines (including biosimilar medicines). NHS England and NHS Improvement. 2017. Available at: https://www.england.nhs.uk/publication/commissioning- framework-for-biological-medicines/ 16. https://www.england.nhs.uk/publication/regional- medicines-optimisation-committee-operating-guidance-and- recruitment-information/ 17. National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy. NICE TA352. August 2015. https://www.nice.org.uk/guidance/ta352 18. National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active ulcerative colitis. NICE TA342. June 2015. https://www.nice.org.uk/guidance/ta342 19. https://www.sps.nhs.uk/articles/rmoc-advisory-statement- sequential-use-of-biologic- medicines/ 20. Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta- analysis. Lancet Gastroenterol Hepatol 2021;6(12):1002-1014. Available from: https://www.thelancet.com/journals/langas/article/PIIS2468 -1253(21)00312-5/fulltext 21. Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta- analysis. Gut 2021 Dec 22;gutjnl-2021-326390. Available at: https://gut.bmj.com/content/gutjnl/early/2021/12/21/gutjnl- 2021-326390.full.pdf 22. Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022;7(2):161-170. Available from: https://www.thelancet.com/journals/langas/article/PIIS2468 -1253(21)00377-0/fulltext